Nasdaq apls.

WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Nasdaq apls. Things To Know About Nasdaq apls.

14 de dez. de 2017 ... Apellis Pharmaceuticals, Inc. [$APLS] rings the closing bell!Rost-9D/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Swedish Orphan Biovitrum ((Sobi)) announce that the CHMP of the EMA has adopted a positive opinion recommending the ...Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of …Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis …

Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its ...

Schwab U.S. Dividend Equity ETF. $74.3216 +0.7716 +1.05%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …

Apellis Pharmaceuticals, Inc. Common Stock (APLS) Institutional Holdings | Nasdaq Skip to main content Created with Sketch. Market Activity Funds + ETFs After-Hours Quotes …

Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and selling therapeutic compounds that work by inhibiting ...Nov 30, 2023 · The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ... The chart below shows the one year performance of APLS shares: Looking at the chart above, APLS's low point in its 52 week range is $42.15 per share, with $94.75 as the 52 week high point — that ...WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Follow. WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of ...

value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ... The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.Apellis Pharmaceuticals (NASDAQ: APLS) · Apellis Pharmaceuticals Return vs. S&P · Apellis Pharmaceuticals Company Info · News & Analysis · Financial Health ...CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops innovative treatments for diseases with unmet needs. In 2023, the FDA approved Syfovre, the only treatment for geographic atrophy (GA), a ...

The APLS stock price is -107.15% off its 52-week high price of $94.75 and 56.65% above the 52-week low of $19.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.29 million shares traded. The 3-month trading volume is 3.02 million shares. Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information

Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM. May 31, 2023 · 9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ... The latest price target for . Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Goldman Sachs on November 9, 2023.The analyst firm set a price target for $74.00 expecting APLS to rise to ... The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals... Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sunrun Inc (Symbol: RUN), where a ...

WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...

Noteworthy Monday Option Activity: BILL, APLS, CVNA. October 09, 2023 — 03:23 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ...Apellis Pharmaceuticals (NASDAQ: APLS) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said ...Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company. May 14, 2021 · WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ... CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ...Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2023 Free Trial Top-Rated Stocks Most-Upgraded Stocks Apellis Pharmaceuticals (APLS) Stock …CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Nov 20, 2023 · Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.

1832 Asset Management L.P. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 405.5% in the 2nd quarter, according to its most …STOCKHOLM, Dec. 13, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today new data demonstrating that ...The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16.Instagram:https://instagram. year to date dow returnmonthly dividend paying mutual fundssimilar apps like robinhoodnasdaq algn news ... Pharmaceuticals (NASDAQ: APLS). Wedbush Analyst forecast on APLS. Laura ChicoWedbush. 08/29/23. $29.00. Hold. -40.94%. Downside. Reiterated. Follow. 0. 0. tellus app reviewus 3 month treasury Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. best mutual funds for roth ira WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...The crowded complement inhibitor field will be watching closely FDA’s decision, due Nov. 26, on C3 inhibitor pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The therapy is one of six complement inhibitors in development for the indication, with the next in line, Zimura avacincaptad pegol from Iveric bio Inc. …Aug 22, 2023 · WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ...